We studied the effects of sera from patients with the acquired immunodeficiency syndrome (AIDS) on interleukin-2 (IL-2) production to help elucidate the mechanism of immubodeficiency. Compared with sera from healthy controls, sera from AIDS patients suppressed phytohemagglutinin (PHA)-induced IL-2 production by normal blood mononuclear cells. Sera from homosexual contacts of AIDS patients and from adults with acute cytomegalovirus infection generally lacked this suppressive activity. The effect of the AIDS sera could not be attributed to absence of a stimulatory or nutritive factor, to inactivation of IL-2, to inhibition of the IL-2 assay, nor to increased turnover of IL-2. The suppressive effect of the sera was not mediated by radiosensitive or T8 antigen-bearing suppressor cells or by increased prostaglandin production or decreased interleukin-1 production. The sera acted directly on the groups of cells that produce IL-2, T cells and large granular lymphocytes; suppression occurred at an early, probably pretranslational, stage. When cells were incubated with AIDS sera and then washed, the suppressive effect persisted. The sera did not cause direct or complement-mediated cytotoxic effects on normal mononuclear cells nor did they suppress PHA-induced interferon production, nor proliferation of T lymphoblasts or lymphocyte lines. The suppressive effect was not mediated by interferon, cortisol, immunoglobulin G or M, or immune complexes. The activity was stable at pH 3, pH 10, and 600C inactivated at 100'(; and not ether extractable. Because IL-2 plays a central role in the development of many immune responses, the serum factor(s) that inhibits IL-2 production could contribute significantly to the immunodeficiency of AIDS.
Introduction
The acquired immunodeficiency syndrome (AIDS)' is frequently manifested by opportunistic infections resulting from a deficiency in cellular immunity (1) (2) (3) (4) (5) (6) (7) (8) . Although life-threatening infections with cytomegalovirus (CMV) are common (9, 10) , patients with AIDS rarely develop cytotoxic T cell responses to CMV-infected cells, and they often have deficient natural killer (NK) cell activity (11, 12) . Inasmuch as these two immunologic functions correlate with favorable outcome of CMV infection in allograft recipients (13, 14) , they may well be important in the defense against CMV infection.
The lymphokine, interleukin-2 (IL-2), plays a role in the development of many aspects of cellular immunity including NK cell activity (15) and cytotoxic T lymphocyte activity (16, 17) . When the peripheral blood mononuclear cells (PBMCs) of patients with AIDS are exposed in vitro to IL-2, often NK cell activity increases to normal levels and cytotoxic activity against CMV-infected cells develops (1 1) . In that lymphocytes from patients with AIDS are deficient in NK cell and cytotoxic T cell activity and these deficiencies can often be corrected by exposure to IL-2 in vitro, it appears that there is a defect in AIDS at the level of stimulation of cytotoxic lymphocyte precursors by IL-2 in vivo. To assess the adequacy of the in vivo exposure of lymphocytes to IL-2 directly is difficult because there is no detectable IL-2 in sera from normal volunteers or patients with AIDS (unpublished observations). Because a serum factor in AIDS that suppresses IL-2 production could account for the abnormalities in cytotoxic activity described above, we tested sera from patients with AIDS for effects on the production of IL-2. We report here the existence of and information regarding a factor(s) in sera from AIDS patients that suppresses production of IL-2 by normal lymphocytes.
Methods
Subjects. All subjects with AIDS and their contacts were being followed at the Clinical Center, National Institutes of Health, Bethesda, MD. Approval for this study was obtained from the appropriate human subjects review committees and informed consent was obtained from all subjects in accordance with regulations for the protection of human subjects. The diagnosis of AIDS was made by the criteria established by the Centers for Disease Control (2). None of the subjects had received interferon (IFN) or other immunomodulating therapy before the time when serum was obtained. AIDS sera were obtained from AIDS patients, of whom all had opportunistic infections. Control sera were obtained from healthy adult laboratory workers. Other sera were obtained from healthy homosexual male volunteers who had been intimate contacts of men with AIDS. Sera from all these subjects were distributed in aliquots, stored at -70'C, and thawed immediately before use. Pooled normal human serum was prepared from sera from four or more healthy adult donors.
Five healthy adult males, seropositive for CMV, had been inoculated subcutaneously with live, nonattenuated Toledo 1 strain of CMV in a recently reported study (18) . All In one experiment, cultures were supplemented with a murine monoclonal antibody to human lymphocyte IL-2 receptors, anti-Tac (20) (kindly provided by Drs. Warren Leonard and Warner Greene). Anti-Tac ascites was added at the initiation of PHA-stimulation at a final dilution of 1:1,000 which was found in preliminary experiments to maximize IL-2 yield. In other experiments, cultures were supplemented with indomethacin (Sigma Chemical Co., St. Louis, MO) which had been dissolved in ethanol at 2 mg/ml and stored at -70'C and/or with interleukin-l (Genzyme Corp., Boston, MA).
IL-2 assay. The measurement of IL-2 was based on its ability to support the proliferation of the IL-2-dependent murine lymphocyte line, CTLL-2 (21). Tests The potency of our laboratory reference standard for IL-2 (Associated Biomedic Systems, Inc., Buffalo, NY) was established by repeated pretesting in triplicate serial twofold dilutions. One unit of IL-2 was defined as the amount of IL-2 present in I ml of that mean dilution of the standard that induced 50% of maximal thymidine uptake by the CTLL-2 cells.
Samples to be tested for IL-2 activity were heated to 560C for 10 min before testing to eliminate the inhibitory effect that some normal sera have in the IL-2 assay (22) . Each sample was initially tested in serial dilutions in parallel with the standard. The graphs of the logarithm of counts per minute vs. the logarithm of the dilution for each sample and for the standard formed smooth curves which were nearly linear and parallel in the range of 5-75% of maximal thymidine uptake. Each sample was retested in triplicate wells at a dilution selected to induce approximately 50% maximal thymidine uptake but not less than a 1:4 dilution. The amount of IL-2 in each sample was determined by comparing the median log counts per minute for the sample replicates to the standard curve to determine the IL-2 content of the wells and multiplying this value by the dilution factor. The IL-2 levels thus determined were generally within 10% of levels determined by probit analysis (21) IFN assay. IFN in culture supernatants and sera was assayed by the inhibition of cytopathic effect of vesicular stomatitis virus as previously described (23), modified by the use of WISH human amnion cells rather than human foreskin fibroblasts. The titers are expressed in international units standardized with reference human leukocyte IFN (G-023-901-52).
Serum lymphocytotoxic activity. Sera were tested for direct lymphocytotoxicity and for complement-mediated lymphocytotoxicity as follows. Mononuclear cells from each of three normal donors were suspended at I X 106 cells/ml and incubated at 370C for I h in 50% serum and 50% medium. After this, rabbit complement (Gibco Laboratories) was added at a 1:6 dilution. After an additional I h at 370C, cells were stained with trypan blue and 200 cells from each well were counted in a hemocytometer to determine viability.
Adsorption and assay of immunoglobulins. Staphylococcal protein A-CL-Sepharose 4B powder (Pharmacia Fine Chemicals) was placed in medium overnight to allow swelling to a gel. To I vol of each test serum was added 2.8 vol of slurry containing 50% protein A-Sepharose gel by volume. This mixture was incubated for 1 h at room temperature with frequent agitation and then centrifuged at 400 g for 10 min. Each supernatant fluid was collected and added to the IL-2 production assay so that 10% of final volume was adsorbed serum.
IgG fraction rabbit anti-human IgM (Cappel Laboratories, Cochranville, PA) was covalently linked to cyanogen bromide-activated Sepharose 4B (Pharmacia Fine Chemicals) after the manufacturer's recommended protocol. These beads were used to adsorb IgM from test sera after the protocol described immediately above for the adsorption of IgG. All IgG ahd IgM levels, before and after adsorption, were measured by single radial immunodiffusion assay (24) .
Cortisol levels. Serum cortisol levels were measuted by radioimmunoassay by Bio-Science Laboratories, Columbia, MD.
Results
Effects of sera on IL-2 production. Sera from AIDS patients and normal controls were tested at a concentration of 10% for their effects on IL-2 production in five experiments that used different mononuclear cell donors for each experiment. The means of the five results for each serum are shown in Fig. 1 .
As can be seen, IL-2 production in the presence of individual sera from patients with AIDS was generally lower than that in the presence of normal control sera (P < 0.01). Four additional AIDS sera (not included among the 13 sera whose test results are depicted in Fig. 1 ) and four control sera were tested for their effects on IL-2 production by mononuclear cells stimulated by PHA at two concentrations, 10 and 2.5 ug/ml. All cultures in this experiment contained pooled normal human serum at 10%. Results are shown in Fig. 2 . At a PHA concentration of 10 gg/ml, mean IL-2 production in the presence of AIDS sera was 59% of control (30 vs . 51 U/ml); at 2.5 ,g/ml, it was only 24% of control (1.3 vs. 5.5 U/ml).
To acquire information regarding the specificity for AIDS of the finding of serum suppression of IL-2 production, we tested in parallel sera from six adult controls, eight patients with AIDS, seven healthy homosexual contacts of AIDS patients, and sera obtained from five adult males before and during experimental, symptomatic, secondary CMV infections. All cultures in this experiment also contained pooled normal human serum at 10%. The results of this experiment are indicated in Fig. 3 . Of interest is that the one homosexual control whose serum appeared to suppress IL-2 production subsequently developed signs and symptoms of hepatitis. The serum we tested was subsequently determined to be positive for hepatitis B surface antigen. At 1 yr of follow-up he remains positive for hepatitis B surface antigen. None of the seven contacts has developed signs of AIDS or lymphadenopathy. The subject with CMV infection whose serum caused suppression of IL-2 production had fever, splenomegaly, and atypical lymphocytosis but lacked detectable viruria or viremia at the time the serum was drawn. Only one other of these five subjects developed fever and splenomegaly but all developed signs and/or symptoms of CMV infection (18) . Nature ofthe serum effect. We next performed experiments to determine whether the lower IL-2 levels found in the presence of AIDS sera resulted from a suppressive effect or from the absence of a stimulatory or nutritive effect. Preliminary experiments had indicated little or no differences in IL-2 production in concentrations of normal serum ranging from 5 to 20%. As can be seen in Fig. 4 , when pooled normal human serum was added to all cultures at a concentration of 10%, IL-2 production was still suppressed by the AIDS sera (P < 0.01) to a degree comparable to the suppression observed in the absence of pooled normal human serum. In subsequent IL-2 production experiments, medium was supplemented with 5 or 10% pooled normal human serum in addition to test sera.
Experiments were performed to determine whether the AIDS sera exerted their effects through inactivation of IL-2 or through inhibition of proliferation of the cells used to assay for IL-2 rather than through suppression of IL-2 production. To each of 24 aliquots of medium we added a test serum (11 control and 13 AIDS) to achieve a final concentration of 10%, and our laboratory standard IL-2 to achieve a final concentra- Experiments were then performed to determine whether the reduced levels of IL-2 in the PHA-stimulated cultures containing AIDS sera resulted from increased uptake of IL-2 by the mononuclear cells rather than from decreased production of IL-2. The results are shown in Table I . Lymphocyte proliferation was measured during PHA stimulation because increased IL-2 uptake might be reflected by increased proliferation. In the presence of AIDS sera proliferation was depressed.
Additionally, anti-Tac monoclonal antibody, which specifically binds the lymphocyte IL-2 receptor (20), was added to PHA-stimulated IL-2 production cultures to block IL-2 uptake. As expected, the addition of anti-TAC increased the levels of IL-2 present in cultures containing either AIDS or normal sera. Nevertheless, the levels of IL-2 found in the cultures with AIDS sera, in comparison with those in the cultures with control sera, remained depressed to the same relative extent as in the absence of anti-Tac antibody.
Timing and target of the suppressive effect. To further elucidate the nature of the effect of AIDS sera on IL-2 production, individual aliquots of normal mononuclear cells were incubated at 370C for 24 h at 107 cells/ml in medium supplemented with 20% serum from one of five healthy controls or one of 10 AIDS patients. Cells were then washed twice and stimulated with PHA in medium supplemented with 10% pooled normal serum plus either an additional 10% pooled normal serum or 10% of the test serum used in the incubation. As shown in Fig. 5 , IL-2 production by cells that had been preincubated in AIDS sera was reduced regardless of whether the AIDS sera were present during stimulation with PHA.
In another experiment, PBMCs were stimulated with PHA in the presence of pooled normal human serum. At various intervals thereafter, either an AIDS serum or additional pooled normal human serum was added. The AIDS serum caused the greatest suppression of IL-2 production when added within 1 h of PHA stimulation. When the serum was added 2 or 4 h (Fig. 6) .
To determine whether the sera act by suppressing IL-2 production directly or by augmenting activity of cells that suppress IL-2 production, sera were tested for their effect on IL-2 production by PBMCs that had been treated to abrogate normal suppressor mechanisms. Indomethacin was used to block prostaglandin production by monocytes; the monoclonal antibody, OKT8, and complement were used to lyse suppressor and cytotoxic T cells; and gamma irradiation was used to inactivate radiosensitive suppressor cells. The data summarized in Table II indicate that each of the treatments employed to block suppressors of IL-2 production resulted in increased IL-2 production in the presence of both normal and AIDS sera.
Nevertheless, the degree of suppression of IL-2 production by AIDS sera remained fairly constant despite these treatments of PBMCs.
Various subpopulations of PBMCs were exposed to an AIDS serum to determine which cells were affected directly by the serum. Compared with IL-2 production by cells not exposed to AIDS serum, IL-2 production by small T cells preincubated in AIDS serum and then mixed with plastic adherent cells was depressed whereas IL-2 production by small T cells not exposed to AIDS serum mixed with plastic adherent cells that had been preincubated in AIDS serum was not depressed (Fig. 7) . Additionally, IL-2 production by purified large granular lymphocytes was suppressed when AIDS serum was present during PHA stimulation.
Exogenous interleukin-1 was added to cultures of PBMCs at the time of PHA stimulation to determine whether this might overcome the suppressive effect of the AIDS sera. Eight AIDS sera that had consistently suppressed IL-2 production were tested for their effects on proliferation of IL-2-dependent T lymphoblasts, of Molt-3, an IL-2-independent T cell line, and of Raji, a B cell line. As indicated in Table  IV , no significant effect of the sera on the thymidine uptake of any of the cell types was observed.
Lack of relationship of serum IFN, cortisol, and immunoglobulin to suppression of IL-2 production. Experiments were performed to determine if the suppressive activity in sera from AIDS patients could be attributed to IFN, cortisol, immunoglobulin, or immune complexes. Of 12 AIDS sera tested for IFN, seven lacked IFN and five had measurable IFN, each at a level of 625 IU/ml. In five experiments, mean IL-2 production was inhibited to 53±23% (mean±SD) of control in the presence of the seven AIDS sera lacking IFN and 51 ± 11% of control in the presence of the five sera with IFN. Six of our serum specimens from AIDS patients were tested for cortisol. Cortisol levels in five were within normal range (5-20 tg/I00 ml; 0.14-0.55 ,umol/liter) and in the other it was 43.2 ug/100 ml (1.19 ,mol/liter). The serum with hydrocortisone at a concentration of 0.1 gg/ml (equivalent to 100 jig/100 ml or 2.75 ,umol/liter in the undiluted serum), IL-2 production was reduced by only 5%. We also tested four control sera and four AIDS sera before and after adsorption of IgG by protein A-CL-Sepharose 4B. As shown in Table V , suppressive activity in the AIDS sera was not significantly altered after removal of '90% of total IgG. In a separate experiment (results not shown) an AIDS serum with less IgG (8.0 g/liter) was similarly adsorbed yielding a final IgG level of 0.29 g/liter (96% removal of IgG) with no loss of inhibitory effects on IL-2 production.
Three sera, two from patients with AIDS and one pooled normal human serum, were adsorbed with anti-human IgMSepharose 4B. After adsorption, IgM was below the limits of detection (0.032 g/liter) in all three sera. PBMCs were stimulated with PHA in medium supplemented to 10% with pooled normal serum and to an additional 10% with one of these three sera either before or after adsorption. Before adsorption, the two AIDS sera suppressed IL-2 production to 9% of that in the culture with pooled normal serum; after adsorption, they suppressed production to 4% of control (data not shown).
To further assess the role of immunoglobulin, four AIDS sera were tested for lymphocytotoxicity against mononuclear cells from three normal donors. Compared with mononuclear cells incubated with normal sera, no significant decrease in viability was observed as a result of incubation with any of the AIDS sera, regardless of whether complement was added.
Preliminary characterization of the suppressive activity in AIDS sera. The suppressive activity was not lost after incubation at pH 3 or 10 for 6 h followed by neutralization. The activity persisted through heating to 60'C for 6 h but -75% of activity was lost during heating to 100IC for 5 min. Suppressive activity persisted after three cycles of freezing and thawing. The activity was not ether extractable.
Discussion
The results presented in this report indicate that sera from AIDS patients contain a factor or factors that suppress IL-2 production by PHA-stimulated mononuclear cells. This suppression could not have resulted from a deficiency of a stimulatory or nutritive factor because it was not overcome by addition of pooled normal human sera. The AIDS serum did not directly inactivate IL-2 nor interfere with the effects of IL-2 on the murine cell line used to assay for IL-2. Indeed, Nor did the suppression of IL-2 production result from suppression of monocyte interleukin-1 production because addition of excess exogenous interleukin-1 did not overcome suppression of IL-2 production. Neither could serum suppression be attributed to augmentation of monocyte-mediated prostaglandin production, a proposed mechanism for normal regulatory inhibition of IL-2 production (25, 26) , in that suppression occurred in the presence of indomethacin, an agent which blocks prostaglandin synthetase activity. Furthermore, our studies on subpopulations of PBMCs indicate that AIDS sera exerted their effect not on monocytes but on the cell types that produce IL-2, T lymphocytes and large granular lymphocytes (27) .
The findings that no suppression occurred when AIDS serum was added 8 h after PHA and submaximal suppression occurred when it was added at 2-4 h should be viewed in light of the fact that IL-2 does not appear in medium until 12-16 h after addition of PHA to PBMCs under the conditions that we employ (unpublished data). Thus, the suppression caused by AIDS sera probably does not occur at the level of translation or secretion but more likely occurs at a transcriptional or pretranscriptional level. The suppression was selective for IL-2 production in that PHA-induced IFN production was not suppressed, viability was not diminished, and the sera did not suppress proliferation of T lymphoblasts, a T cell line, or a B cell line. Also of note regarding the mechanism of suppression is that lymphocytes incubated in AIDS serum for 24 h and then washed remained suppressed in their ability to produce IL-2. This may reflect either internalization of suppressor substance(s) in the lymphocytic cytoplasm or an effect of the suppressor substance(s) on lymphocytes which is not readily reversible.
Although our tests generally discriminated well between AIDS sera and control sera (particularly at the lower dose of PHA), there were two noteworthy examples of overlap. One of several healthy homosexual men had serum that suppressed IL-2 production into the range observed with the AIDS sera. This subject was a recurrent sexual contact of a patient with AIDS; however, he remains free of AIDS at 12 mo of followup. Also of note is that his serum was hepatitis B surface antigen positive, and he subsequently developed signs and symptoms of acute and chronic hepatitis. One of five healthy subjects given experimental secondary CMV infection also developed serum suppressive activity comparable to that observed in AIDS patients. These five subjects demonstrated immunologic abnormalities typical of systemic CMV infection (18) . We have yet to determine whether the suppressive factor(s) in the subject with hepatitis and the subject with CMV infection is (are) identical to the factor(s) in patients with AIDS. Therefore the serum suppression observed in AIDS may be specific for AIDS or may represent a less specific response to viremia, immunosuppression, and/or other factors yet to be determined.
We performed tests to determine whether the factor(s) in sera from AIDS patients which suppressed IL-2 production was abnormal IFN, elevated cortisol, antibodies, or immune complexes. Acid-labile aIFN is often present in sera of patients with AIDS (28) . We found no correlation between the presence of IFN in AIDS sera and the suppressive effects on IL-2 production. Cortisol can impair IL-2 production (16, 29) and may be elevated during illness, but the cortisol levels that we found in most AIDS sera were within normal limits, and none were high enough to account for the suppressive effect on IL-2 production. Sera were treated with immunoadsorbents to remove IgG, IgM, and immune complexes. Removal of 90% of IgG from several sera did not diminish their suppressive activity; nor did removal of nearly all IgM fromn two sera. Additionally, we found no antibody and complement-mediated lymphocytotoxic activity in the four sera we tested.
The suppressive activity was stable at pH 3 and 10, stable at 60'C, inactivated at 1000C, and not extracted by ether. Since human T cell lymphotropic virus III is inactivated by treatment at 60'C for 6 h (unpublished data) and is also ether sensitive, these findings indicate that the suppressive activity does not require live human T cell lymphotropic virus III in the sera. The lack of ether extractability suggests that the activity is not a lipid or other highly hydrophobic molecule.
The degree of suppression of IL-2 production that we observed may underestimate the actual degree of suppression attributable to the serum factor in vivo. When the concentration of PHA was lowered and less IL-2 was produced, the suppression was of a relatively greater degree. When we employ antigenic stimuli such as allogenic cells or influenza virusinfected lymphocytes instead of PHA, we typically find even lower levels of IL-2 produced (generally <2 U/ml; unpublished observations). The suppressive effect of the AIDS serum factor(s) might be more profound in vivo than in this study because of the weaker antigenic stimuli, the longer period of exposure of lymphocytes to serum, and because the factor(s) should be 10-fold more concentrated in the patients' circulation than in culture media supplemented to 10% with serum.
The nature of the effect of the serum suppressive factor(s) suggests an important role in the pathophysiology of AIDS. As indicated in the introduction, many patients with AIDS and CMV infection lack cytotoxic lymphocytes directed against CMV-infected cells and are deficient in NK activity yet have IL-2-responsive precursor cells, (11, 12) . This arrest in the development of mature cytotoxic effector cells could readily be explained by suppression of IL-2 production in vivo; in such a manner the serum factor that we describe could contribute significantly to the increased susceptibility to infection of patients with AIDS. Furthermore, due to the central role that IL-2 plays in the development of many immune responses, impaired IL-2 production could account for several of the previously described immunologic abnormalities in patients with AIDS such as low NK activity (11, 12) and impaired delayed-type hypersensitivity reaction to skin test antigens (3) (4) (5) (6) (7) (8) . Because the suppressive activity of AIDS sera persisted in normal lymphocytes after washing, it might also contribute to functional abnormalities observed in AIDS lymphocytes when stimulated in vitro such as the impaired proliferative response to mitogens (3) (4) (5) (6) . Additionally, suppression of IL-2 production could account for the suppression of mitogen-induced proliferation of normal lymphocytes attributed to sera from patients with AIDS (30) . Indeed, because IL-2 supports the proliferation of helper and suppressor T lymphocytes, any immunologic function involving regulation by these cells could be altered by the factor suppressing IL-2 production.
The finding that important immunologic abnormalities in AIDS may be attributable to a serum factor(s) has significant implications regarding research into the immunopathology of AIDS and regarding the clinical management of AIDS. The serum factor may be produced either by an infectious agent of AIDS or by the patient in response to the agent. Evidence strongly suggests that a retrovirus is probably the causative agent of AIDS (31) (32) (33) , it is of interest that inactivated feline leukemia retrovirus particles can suppress IL-2 production by lymphocytes (34) . Additionally, soluble factors which suppress IL-2 production have been reported to be produced by spleen cells (35) , melanoma cells (36) , and monocytes (25, 26) . Cultures of mononuclear cells from AIDS patients have been reported to produce an immunosuppressive factor, but this factor could not account for the serum suppressive effect that we observed in that it did not inhibit proliferation of PBMCs in response to PHA (37) . We are currently conducting studies designed to determine the source of the serum factor, to understand better its actions, and to purify and characterize it. These studies should provide new insights into the immunopathology of AIDS and may lead to techniques for blocking the production of the factor, removing or inactivating it, or blocking, bypassing, or countering its effects and may thus contribute to the rational design of immunotherapy for AIDS.
